MINUTE medical - Experts for Radionuclide Therapy Vienna

MINUTE medical – Prof. Dr Markus Hartenbach
Molecular Internal NUclide ThErapy
Nuclear Medicine Specialists
Vienna, Austria

MINUTE medical – Prof. Dr Markus Hartenbach - Logo

Treatment Focus

  • Prostate Cancer
  • PSMA therapy (Lutetium, Actinium)
  • Neuroendocrine tumors (NET)
  • Peptide receptor radionuclide therapy (PRRT)
  • PSMA PET/CT (Gallium-68)
  • Therapy of bone metastases (Radium-223)

Medical Range

Diagnostic Range of Services

  • 68Gallium PSMA PET/CT
  • 68Ga Somatostatin receptor PET/CT

Therapeutic Range of Services

  • PSMA therapy (lutetium, actinium)
  • Peptide receptor radionuclide therapy (PRRT)
  • Therapy of bone metastases (Radium-223)

About MINUTE medical – Prof. Dr Markus Hartenbach

MINUTE medical offers specific, personalized cancer therapies with the highest professional, and scientific competence in the heart of Vienna.

As a nuclear medicine institute, MINUTE medical specializes in therapy and diagnostics using radioligands. This innovative treatment is based in principle on the knowledge that certain tumor cells carry specific receptors on their surface, which can serve as docking stations for so-called radiopharmaceuticals. As a result, the tumor cells can be irradiated very effectively, and the damage to the surrounding tissue can be reduced to a minimum.

The technology, developed according to the latest scientific findings, is paired with personalized individual care, guaranteeing extremely discreet treatment.

The experts led by the internationally renowned scientists Prof. Dr Markus Hartenbach, Prof. Dr Alexander Haug, and Prof. Dr Wolfgang Wadsak undoubtedly pioneered this now-established technology.

Radioligand Therapy for Prostate Cancer

The 177Lutetium-PSMA radioligand therapy is based on discovering that the degenerated cells of a prostate carcinoma present a very specific enzyme on the surface of their cell membrane. This prostate-specific membrane antigen (PSMA) serves as a docking station, so to speak, for the 177Lu-PSMA radioligands, which then exert their therapeutic effect through the radiating isotope of the chemical element lutetium. Depending on the severity and distribution pattern of the disease, Prof. Hartenbach's team also uses the alpha emitter actinium-225 instead of the beta emitter lutetium-177.

The radiation of these nuclides spreads only in a tiny radius of a few micrometers but is sufficient to effectively damage/destroy the cancer cell in question. Furthermore, collateral damage to surrounding healthy tissue is minimal thanks to this precise navigation of the radiation source to the target cells. This is the reason for the enormous advantage over radioactive irradiation by an external, comparatively imprecise radiation source.

By replacing the therapeutic emitter (lutetium or actinium) with the positron emitter gallium-68, the radioligands can also be used for nuclear medicine diagnostics of the same target structure. In this way, therapy can be effectively monitored.

Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors (PRRT).

Neuroendocrine tumors (NET) often respond to peptide receptor radionuclide therapy (PRRT). This treatment method also applies the finding that tumor cells of this type have so-called somatostatin receptors on the cell membrane in high abundance. The beta-emitter lutetium-177 has proven to be a therapeutic nuclide of choice in this therapy. Lutetium-177 is chemically fixed to the appropriate peptide (e.g., DOTA-TATE), a substance that fits like a "key" into the "lock," namely the somatostatin receptors on the tumor cells. This precise targeting of the radioligand allows the lutetium-177 to be navigated via the bloodstream directly to the cancer cells and destroy/damage them.

Radionuclide Therapy for Bone Metastases (Radium-223 Dichloride).

The principle of therapy with radionuclides is also very successful in bone metastases. Some tumors activate certain cell groups that are responsible for bone formation, the so-called osteoblasts. These are referred to as osteoblastic bone metastases. Osteoblasts typically embed calcium ions into the bone substance. If these bone-building cells are now offered radium ions, they are also embedded into the bone matrix due to their chemical relationship to calcium. The osteoblasts activated by the cancer are consequently effectively irradiated by self-embedded radium-223 dichloride. This also exerts its effect on the tumor cell through various mechanisms and, therefore, slows these metastases' progression.

Molecular Imaging: 68Gallium PSMA-PET/CT for Prostate Cancer Diagnosis and 68Ga-Somatostatin Receptor PET/CT for Neuroendocrine Tumors

Innovative radioligand technology enables high-precision molecular diagnostic capabilities. As an indispensable component of radioligand therapy, it combines diagnostics and treatment into a new approach called "theranostics." This is because radiopharmaceuticals, i.e., radioactive drugs that bind precisely to the specific surface structures of cancer cells, can also be charged with purely imaging nuclides, such as gallium-68, for diagnostic purposes (so-called radiodiagnostics). Through intravenous administration and distribution in the body, increased accumulation in the target structures throughout the body can be detected by nuclear imaging. Thus, this whole-body imaging can visualize those tissues that are diseased or metastatic.

Additional Services

The architecturally sophisticated combination of functionality and the highest level of discretion was a key factor in establishing this state-of-the-art institution. To offer patients the highest level of comfort, additional organizational and medical services are also provided. The MINUTE medical team supports patients from arrival to departure and during their stay in Austria's historical capital to make the medically necessary stay in Vienna as pleasant as possible.

Patients also benefit directly from the most modern medical care in terms of interdisciplinary cooperation. MINUTE medical works in an expert network in close collaboration with renowned specialists in pathology, urology, oncology, and radiation/proton therapy to ensure patients' best possible treatment and diagnostics.

For more information, please visit the MINUTE medical website.


Curriculum Vitae

Prof. Dr Markus Hartenbach

Since 08/2018 Managing Director of MINUTE medical GmbH Vienne
12/2015 and 10/2018 Assistant and Associate Professor of Nuclear Medicine at the Medical University of Vienna, Austria.
03/2014-10/2018 Senior Physician and Head of PET / MRI at Vienna General Hospital of the Medical University of Vienna, Austria
01/2013-02/2014 Parental Leave
03/2012-12/2012 Senior Physician and Representative Head of the Nuclear Medicine Section, German Armed Forces Hospital Ulm. Advanced Training in Radiology at the Interdisciplinary PET / CT
03/2012 Medical Specialist in Nuclear Medicine
03/2011-02/2012 Advanced Training CT / MRI, Clinic for Radiology, German Armed Forces Hospital Ulm
01/2010-02/2011 Ward Physician and Advanced Training PET / CT, Clinic for Nuclear Medicine, Ludwig-Maximilians-University Munich, Campus Großhadern, Medical Director: Prof. Dr P. Bartenstein
12/2009 Directing Senior Physician and Representative Head of Nuclear Medicine, German Armed Forces Hospital Ulm, Germany
12/2009 Radiation Protection Expertise
03/2009 Promotion to Senior Physician German Armed Forces Hospital Ulm
12/2008 Golden Cross of Honor of the German Armed Forces
07/2008-12/2009 Assistant Physician Nuclear Medicine German Armed Forces Hospital Ulm
06/2007-06/2008 Research Associate at the Institute for Radiobiology of the German Armed Forces in Munich
11/2006 Certification Investigator and Study Director (Competence Center for Clinical Studies at the University of Tübingen)
10/2006 Promotion an der Universität Ulm
11/2005-05/2007 Assistant Physician Nuclear Medicine German Armed Forces Hospital Ulm
11/2005 University degree and Promotion to Medical Officer
10/1999-11/2005 Study of Human Medicine at the University of Ulm
01/1999-09/1999 Officer Training Courses I and II in Horb a. Neckar and Munich
01/1999 Nomination as Medical Officer Candidate
07/1998-12/1998 Military Service in Kempten and Munich
05/1998 High School Diploma (Abitur) at Gymnasium Markt Schwaben, Bavaria


Prof. Dr rer. nat. Wolfgang Wadsak

Since 01/2019 Secretary/Treasurer of the European Association of Nuclear Medicine (EANM)
Since 2017 Scientific Leader - Area 1 (Data & Technologies), CBmed Ltd (Center for Biomarker Research in Medicine; Graz)
Since 10/2016 Coordinator of Vienna Activities, Projects and Labs, CBmed Ltd (Center for Biomarker Research in Medicine; Graz)
Since 2016 Safety Officer
Since 2016 Secretary/Treasurer of the Austrian Society for Nuclear Medicine and Molecular Imaging (OGNMB)
Since 2016 Director of the "Alliance for the Promotion of Radiopharmaceutical Sciences
Since 2015 Auditor of the European Association of Nuclear Medicine (EANM)
Since  2015 Board member of the Austrian Society of Nuclear Medicine and Molecular Imaging (OGNMB)
Since 2013 Head of the "Development of Imaging Probes" Node in the Medical Imaging Cluster (MIC) @MedUni Vienna
Since 2012 Associate Professor of Medical Radiochemistry, Head of the Department of Medical Radiochemistry and Biomarker Development, Medical University of Vienna
2011 4-Month Scientific Internship at ETH Zurich, Switzerland
2010-2012 Assistant Professor, Department of Radiochemistry and Biomarker Development, Medical University of Vienna
2009-2010 Senior Post-Doc, Medical University of Vienna
Since 2009 Lecturer for "Physiology and Pathology for Functional Imaging 1" at the University of Applied Sciences Wiener Neustadt (Master Program "MedTech")
2009 Habilitation; Medical Radiochemistry, Medical University of Vienna
Since 2005 Radiation Safety Officer - Laboratories for Radiochemistry, Radiopharmacy, Psychiatry and Laboratory for Preclinical Imaging (PIL)
Since 2005 Lecturer for "Medical Radiochemistry 1+2" at the University of Vienna
Since 2004 Trainer and consultant for Bayer AG (former Schering AG), Vienna for radioimmunotherapy
Since 2003 Lecturer for "Radiopharmacy" at the Academy for Radiology Technologists in Vienna (now: FH Vienna)
2003-2004 Postgraduate Studies in Radiopharmaceutical Chemistry, ETH Zurich/ Universities of Frankfurt and Leipzig
Since 2001 Production Manager for PET Radiopharmaceuticals, University Clinic for Nuclear Medicine, Medical University of Vienna
2001-2009 University Assistant, Medical University of Vienna
2000-2004 Doctoral Studies (Radiochemistry), University of Vienna and Scientific Assistant, University Department of Nuclear Medicine, Medical University of Vienna
1991-1999 Master Studies in Chemistry, University of Vienna


Prof. Dr Alexander Haug

Since 2019 Head of the Christian Doppler Laboratory for "Applied Metabolomics"
2016 Alavi-Mandell Award of the Society of Nuclear Medicine as Senior Author, twice
Since 2013 Representative Director of the Department of Nuclear Medicine at the University Hospital AKH Vienna, Head of the Therapy Ward, and Associate Professor of Nuclear Medicine
2013 Habilitation for Molecular Imaging and Therapy of Neuroendocrine Tumors, venia docendi at the Ludwig-Maximilians-University Munich
2011 Wolfgang Becker Award of the Bavarian Society of Nuclear Medicine
2010 Nuclear Oncology Council Young Investigator Award of the Society of Nuclear Medicine, 3rd Place.
2010 Award of the Young Professionals Committee - Clinical Sciences of the Society of Nuclear Medicine (SNM), 2nd Place
As of 2009 Head of the Therapy Ward, incl. Outpatient Care
2009 Specialist in Nuclear Medicine
2004-2009 Training in Nuclear Medicine at the University Hospital Munich
2003 Graduation from Ludwig-Maximilians-University Munich, Human Medicine
07/1995-12/1996 Military service
05/1995 High School Diploma (Abitur) at Ludwigsgymnasium in Straubing, Bavaria

Medical Team

  • Prof. Dr. med. Markus Hartenbach - PortraitProf. Dr Markus Hartenbach
    Medical Specialist in Nuclear Medicine
  • Prof. Dr. rer. nat. Wolfgang Wadsak - PortraitProf. Dr rer. nat. Wolfgang Wadsak
    Certified Radiopharmacist and Radiation Protection Representative
  • Prof. Dr. med. Alexander Haug - PortraitProf. Dr Alexander Haug
    Medical Specialist in Nuclear Medicine


  • Outpatient radioligand therapy
  • Interpreter
  • Transfer service
  • Highest discretion/privacy
  • Individual care directly by renowned specialists
  • A private institution with state-of-the-art equipment


City Center Vienna 300 m
Vienna Main Station 4.9 km
Vienna Airport 20.7 km

Information About Vienna

Specialist doctors and medical centres in Vienna

The Austrian capital is located in the east of the country at the junction of the eastern Alpine foothills and the Pannonian Plain. Its namesake is the small river Wien, but the city is associated with the much larger Danube River that also flows by the city. Vienna is divided into so-called districts, so the old town is also the Inner District, around which the other 22 districts are arranged concentrically. In 2001 the historic city centre was declared a UNESCO World Heritage Site.


Benefits Programme on Site

Lufthansa Mobility Partner

PRIMO MEDICO is an accredited partner of Lufthansa Health & Medical. Benefit as a member or user of PRIMO MEDICO from special terms that provide you and your travelling companion with discounts on a variety of fares offered by Lufthansa, SWISS, Austrian and Brussels Airlines.


Professional Aviation Solutions

Professional Aviation Solutions is a young, motivated team of experienced aircraft charter experts, which collaborates with only the most reputable airlines.


Ruby Hotels Vienna - Lean Luxury Design Hotels

Ruby Hotels Vienna - a Lean Luxury Design Hotels - five-star accommodation in the heart of the city at the price of a budget hotel. Small but attractive rooms with excellent features and relaxed design.


Grand Hotel Vienna

The Grand Hotel Vienna is one of the most modern and luxurious hotels in Europe. Its location in the heart of Vienna is unique – right next to the ring road and only a few steps away from the State Opera and the beginning of Kärntnerstraße. The five-star deluxe hotel, which is part of the “Leading Hotels of the World,” combines extravagant features, high-quality service, and exquisite gastronomy.


Agent CS

Agent CS creates space so that you can concentrate on your most important tasks - an innovative service agency which uses existing networks in a wide variety of areas to provide you with a solution customised for you.



MINUTE medical – Prof. Dr Markus Hartenbach
Molecular Internal NUclide ThErapy

Hörlgasse 14/5, A-1090 Vienna

T: +43 1 358 9334


For private patients and self-paying patients

By Appointment

OUR GUIDELINES Our guidelines

At PRIMO MEDICO, you will only find reputable medical authorities who were selected according to strict guidelines. Experience, innovative treatment techniques or reputation in science and research play an important role here.